Drugs / CHF10067
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05513950 | Jan 2023 → Jun 2024 | idiopathic pulmonary fibrosis | Chiesi Farmaceutici S.p.A. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07516951 | Jul 2026 → Feb 2028 expected | idiopathic pulmonary fibrosis | Chiesi Farmaceutici S.p.A. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHF10067 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05513950 ↗ |
| Known as | Zampilimab | “A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis” NCT07516951 ↗ |
| Route | Intravenous | “CHF10067 was administered intravenously as single ascending doses” NCT05513950 ↗ |